Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 3, 2005, Pages 761-764

  Lindsley, Craig W ^a   Zhao, Zhijian ^a   Leister, William H ^a   Robinson, Ronald G ^a   Barnett, Stanley F ^a   Defeo Jones, Deborah ^a   Jones, Raymond E ^a   Hartman, George D ^a   Huff, Joel R ^a   Huber, Hans E ^a   Duggan, Mark E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Kinase cancer; PKB

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; PYRAZINONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ALLOSTERIC REGULATION; APOPTOSIS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19944431003     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.11.011     Document Type: Article

References (21)

1. For excellent reviews on Akt see: J.R. Graff Expert Opin. Ther. Targets 6 2002 103
2. K.M. Nicholson, and N.G. Anderson Cell. Signal. 14 2002 381
3. Q. Li, and G.-D. Zhu Curr. Top. Med. Chem. 2 2002 939
4. S. Hanks, and T. Hunter FASEB 9 1995 576
5. M.J. Zinda, M.A. Johnson, J.D. Paul, C. Horn, B.W. Konicek, Z.H. Lu, G. Sandusky, J.E. Thomas, B.L. Neubauer, M.T. Lai, and J.R. Graff Clin. Cancer Res. 7 2001 2475
6. J.H. Hsu, Y. Shi, L.P. Hu, M. Fisher, T.F. Franke, and A. Lichtenstein Oncogene 21 2002 1391
7. C. Page, H. Lin, Y. Jin, V.P. Castle, G. Nunez, M. Huang, and J. Lin Anticancer Res. 20 2000 407
8. J.Q. Cheng, B. Ruggeri, W.M. Klein, G. Sonoda, D.A. Altomare, D.K. Watson, and J.R. Testa Proc. Natl. Acad. Sci. U.S.A. 93 1996 3636
9. D. Haas-Kogan, N. Shalev, M. Wong, G. Mills, G. Yount, and D. Stokoe Curr. Biol. 8 1998 1195
10. S.P. Staal Proc. Natl. Acad. Sci. U.S.A. 84 1987 5034
11. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Cancer Res. 61 2001 3986
12. A.P. Kozikowski, H. Sun, J. Brognard, and P.A. Dennis J. Am. Chem. Soc. 125 2003 1144
13. C.B. Breitenlechner, T. Wegge, L. Berillon, K. Graul, K. Marzenell, W. Friebe, U. Thomas, R. Huber, R.A. Engh, and B. Masjost J. Med. Chem. 47 2004 1375
14. For Akt enzyme assay details and the proposed model for the allosteric mode of inhibition of these inhibitors, see: Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R.; Huber, H. E. Biochemistry, in press
15. For details on the Akt IPKA assay, the caspase-3 assay and the in vivo experiment with 16h, see: Jones, R. E.; Defeo-Jones, D.; Fu, S.; Barnett, S. F.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R.; Huber, H. E.; Lindsley, C. W.; Zhao, Z.; Duggan, M. E. Mol. Cancer Ther., in press
16. C.W. Lindsley, Z. Zhao, and W.H. Leister Tetrahedron Lett. 43 2002 4225
17. W. Zhang, D.P. Curran, and C.H.-T. Chen Tetrahedron 58 2002 3871
18. W. Leister, K. Strauss, D. Wisnoski, Z. Zhao, and C.W. Lindsley J. Comb. Chem. 5 2003 322 Note, all compounds purified to >98% by mass-guided prep HPLC and fully characterized by LCMS, HRMS, and NMR
19. Z. Zhao, D.D. Wisnoski, S.E. Wolkenberg, W.H. Leister, Y. Wang, and C.W. Lindsley Tetrahderon Lett. 45 2004 4873 and references cited therein
20. A.A. Patchett, and R.P. Nargund Annu. Rep. Med. Chem. 35 2000 289 and references cited therein
21. G.W. Rokhlin, N.V. Guseva, A.F. Tagiyev, R.A. Glover, and M.B. Cohen The Prostate 52 2002 1 and references cited therein